| NCT07181109 | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | RECRUITING | PHASE3 | 2025-10-24 | 2030-10-29 | 2030-10-29 |
| NCT07214727 | A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease | NOT_YET_RECRUITING | PHASE1 | 2025-10-09 | 2030-03-31 | 2030-03-31 |
| NCT07052903 | TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | PHASE3 | 2025-07-02 | 2032-11-30 | 2030-05-28 |
| NCT06845202 | A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM | RECRUITING | PHASE1, PHASE2 | 2025-03-03 | 2027-08-31 | 2027-08-31 |
| NCT06600321 | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | RECRUITING | PHASE1 | 2024-12-30 | 2027-10-31 | 2027-09-30 |
| NCT06679946 | A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | ENROLLING_BY_INVITATION | PHASE3 | 2024-12-03 | 2028-05-30 | 2028-05-30 |
| NCT06659640 | A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | RECRUITING | PHASE1, PHASE2 | 2024-11-11 | 2028-06-22 | 2026-08-19 |
| NCT06675565 | A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers | COMPLETED | PHASE1 | 2024-11-05 | 2025-09-08 | 2025-09-08 |
| NCT06585449 | A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease | RECRUITING | PHASE1 | 2024-10-14 | 2028-07-05 | 2028-07-05 |
| NCT06423352 | A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension | COMPLETED | PHASE1, PHASE2 | 2024-06-05 | 2025-07-17 | 2025-07-17 |
| NCT06393712 | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy | RECRUITING | PHASE2 | 2024-05-17 | 2029-11-01 | 2027-07-01 |
| NCT06272487 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-02-29 | 2025-12-19 | 2025-04-02 |
| NCT05761301 | A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM | TERMINATED | PHASE1, PHASE2 | 2023-03-10 | 2025-04-03 | 2025-04-03 |
| NCT05661916 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-01-16 | 2025-09-30 | 2025-09-30 |
| NCT05256810 | A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout | TERMINATED | PHASE1, PHASE2 | 2022-02-25 | 2023-01-25 | 2023-01-25 |
| NCT05231785 | A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD | RECRUITING | PHASE1 | 2022-02-04 | 2029-03-28 | 2029-03-28 |
| NCT05161936 | A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels | TERMINATED | PHASE2 | 2022-01-27 | 2022-11-01 | 2022-11-01 |
| NCT05103332 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | COMPLETED | PHASE2 | 2021-11-05 | 2024-09-13 | 2023-12-11 |
| NCT04936035 | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension | COMPLETED | PHASE2 | 2021-07-07 | 2024-12-05 | 2023-04-04 |
| NCT04565717 | A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) | TERMINATED | PHASE1 | 2020-10-09 | 2023-12-21 | 2023-01-06 |
| NCT04152200 | A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 | COMPLETED | PHASE3 | 2020-01-21 | 2025-06-23 | 2021-05-18 |
| NCT04153149 | HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-11-26 | 2026-12-01 | 2024-05-08 |
| NCT03841448 | A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) | TERMINATED | PHASE2 | 2019-09-30 | 2023-06-27 | 2022-03-17 |
| NCT03997383 | APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-09-04 | 2027-03-01 | 2022-06-20 |
| NCT03934307 | A Study to Evaluate ALN-AGT01 in Patients With Hypertension | COMPLETED | PHASE1 | 2019-05-01 | 2023-01-04 | 2022-04-20 |
| NCT03905694 | A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 | COMPLETED | PHASE3 | 2019-04-22 | 2024-07-26 | 2020-06-29 |
| NCT03862807 | Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant | COMPLETED | PHASE3 | 2019-03-27 | 2020-10-20 | 2020-10-06 |
| NCT03759379 | HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-02-14 | 2025-10-29 | 2020-11-10 |
| NCT03767829 | A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease | TERMINATED | PHASE1, PHASE2 | 2018-12-05 | 2020-06-25 | 2020-06-25 |
| NCT03681184 | A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 | COMPLETED | PHASE3 | 2018-11-27 | 2024-01-12 | 2019-11-05 |
| NCT03505853 | A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP) | COMPLETED | PHASE1 | 2018-04-26 | 2019-01-10 | 2018-11-16 |
| NCT03350451 | An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1 | COMPLETED | PHASE2 | 2018-04-04 | 2023-02-07 | 2023-02-07 |
| NCT03338816 | ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) | COMPLETED | PHASE3 | 2017-11-16 | 2021-05-31 | 2019-01-31 |
| NCT03303313 | A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome | WITHDRAWN | PHASE2 | 2017-09-19 | 2018-09-12 | 2018-09-12 |
| NCT02949830 | A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP) | COMPLETED | PHASE1, PHASE2 | 2016-10 | 2021-11-05 | 2021-11-05 |
| NCT02826018 | A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection | TERMINATED | PHASE1 | 2016-06-24 | 2017-10 | 2017-10 |
| NCT02797847 | A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects | COMPLETED | PHASE1 | 2016-06-07 | 2018-01-12 | 2018-01-12 |
| NCT02706886 | Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1 | COMPLETED | PHASE1, PHASE2 | 2016-03-08 | 2019-01-23 | 2019-01-23 |
| NCT02595983 | The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant | COMPLETED | PHASE2 | 2015-10 | 2017-02-06 | 2017-02-06 |
| NCT02510261 | The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) | COMPLETED | PHASE3 | 2015-07-16 | 2022-11-23 | 2022-11-23 |
| NCT02503683 | A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease | TERMINATED | PHASE1 | 2015-07-09 | 2018-01-03 | 2018-01-03 |
| NCT02452372 | A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) | COMPLETED | PHASE1 | 2015-05-06 | 2017-09-06 | 2017-09-06 |
| NCT02352493 | A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH | COMPLETED | PHASE1, PHASE2 | 2015-01 | 2017-08 | 2016-04 |
| NCT02319005 | ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | COMPLETED | PHASE3 | 2014-12 | 2017-03-30 | 2017-03-30 |
| NCT02314442 | A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C) | COMPLETED | PHASE1 | 2014-12 | 2015-11 | 2015-05 |
| NCT02292186 | A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis | COMPLETED | PHASE2 | 2014-10 | 2017-02-22 | 2017-02-22 |
| NCT02053454 | A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers | COMPLETED | PHASE1 | 2014-01 | 2014-06 | 2014-03 |
| NCT01981837 | Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis | COMPLETED | PHASE2 | 2013-12 | 2015-01 | 2014-10 |
| NCT01960348 | APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis | COMPLETED | PHASE3 | 2013-11 | 2017-08 | 2017-08 |
| NCT01961921 | The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) | COMPLETED | PHASE2 | 2013-10 | 2016-08 | 2016-07 |
| NCT01814839 | A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers | COMPLETED | PHASE1 | 2013-03 | 2015-05 | 2015-04 |
| NCT01617967 | Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis | COMPLETED | PHASE2 | 2012-05 | 2014-01 | 2013-10 |
| NCT01559077 | Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects | COMPLETED | PHASE1 | 2012-03 | 2012-11 | 2012-06 |
| NCT01437059 | Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C) | COMPLETED | PHASE1 | 2011-09 | 2012-09 | 2012-03 |
| NCT01158079 | Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment | COMPLETED | PHASE1 | 2010-07 | 2012-09 | 2012-08 |
| NCT01148953 | Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis | COMPLETED | PHASE1 | 2010-06 | 2012-02 | 2012-01 |
| NCT01065935 | Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) | COMPLETED | PHASE2 | 2010-02 | 2012-05 | 2012-04 |
| NCT00882180 | Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement | COMPLETED | PHASE1 | 2009-03 | 2011-08 | 2011-07 |
| NCT00658086 | Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) | COMPLETED | PHASE2 | 2008-04 | 2009-06 | 2009-04 |
| NCT00496821 | Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus | COMPLETED | PHASE2 | 2007-07 | 2007-11 | |